Tonix Pharmaceuticals Holding Cash Flow Statement (2023-2025) | TNXP

Cash Flow Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Operating Activities
Net Income -27.98M-27.32M-21.35M-77.31M-15.84M-22.48M-16.05M-27.67M-31.84M
Share-based Compensation 2.79M2.36M2.08M2.04M1.69M1.15M1.04M0.89M0.88M1.42M1.92M
Gains from Investment Securities 8.24M1.39M1.38M774.009.75M0.85M0.36M0.67M1.15M1.16M
Asset Writedowns and Impairment -0.96M
Non-cash Items 0.89M0.24M0.25M0.26M0.57M0.02M0.07M936.000.00M0.00M0.00M
Cash from Operations -32.91M-23.37M-23.39M-22.34M-17.57M-9.92M-18.80M-14.63M-16.58M-14.83M-28.78M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 0.30M0.13M0.21M0.20M0.07M
Depreciation & Amortization (CF) 0.89M0.90M1.22M1.26M1.21M1.21M0.51M0.50M0.49M0.48M0.46M
Change in Working Capital
Change in Receivables 1.64M-1.30M-0.37M-0.99M1.19M
Change in Inventory -1.29M-1.16M-1.25M-0.05M-0.27M0.13M-1.22M
Change in Account Payables 0.57M-1.15M1.02M-3.94M2.98M3.73M-6.36M0.58M-0.35M3.06M1.02M
Change in Accured Expenses -2.96M1.36M-1.05M4.43M-1.75M0.91M0.47M1.55M-2.95M3.36M1.25M
Other Working Capital Changes 1.21M-1.47M-3.07M1.76M1.35M-2.37M0.34M-2.94M0.62M-0.13M1.68M
Investing Activities
Capital Expenditures 3.80M1.84M1.81M0.44M0.11M0.01M0.00M0.01M0.53M0.96M
Sales of Property, Plant and Equipment 0.01M
Cash from Investing Activities -3.80M-24.02M-0.82M-0.43M-0.11M-0.01M-0.00M-0.01M-2.54M-0.96M
Financing Activities
Cash from Financing Activities -11.50M1.03M6.27M40.71M-0.21M7.03M42.91M85.15M49.53M10.99M94.86M
Additional items
Exchange Rate Effect -0.04M-0.01M-0.01M-0.00M0.00M-0.02M0.02M-0.01M-0.00M-0.00M
Change in Cash -48.25M-46.36M-17.94M17.93M-17.90M-2.89M24.08M70.55M32.94M-6.38M65.11M
Beginning Cash Balance 120.23M71.97M24.86M7.01M24.95M7.05M4.16M28.23M98.78M131.71M124.94M
Free Cash Flow -36.71M-25.21M-25.20M-22.78M-17.68M-9.92M-18.81M-14.63M-16.59M-15.36M-29.74M
Net Cash Flow -48.21M-46.36M-17.93M17.94M-17.89M-2.89M24.09M70.52M32.95M-6.38M65.12M